Physician profile
Jerry D Walker
NPI 1649238866
$1,492.61
in general payments reported to CMS, 2019-2025
24 companies · $452 in 2025
The $452 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $273 · 2023: $348 · 2024: $419 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,219.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $220.24 | 2022-2025 | |
| Pfizer INC. | $217.08 | 2022-2025 | |
| Medtronic, INC. | $125.58 | 2023-2025 | Cobalt Dr Mri Surescan, Adapta, Micra |
| Merck Sharp & Dohme LLC | $114.99 | 2022-2025 | Verquvo, Winrevair |
| Astrazeneca Pharmaceuticals Lp | $106.33 | 2022-2025 | Farxiga |
| Boston Scientific Corporation | $92.86 | 2022-2025 | Watchman Flx, Synergy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.89 | 2023-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $68.16 | 2023-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $56.24 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $56.08 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $50.84 | 2022-2025 | Camzyos, Eliquis |
| Daiichi Sankyo INC. | $46.69 | 2023-2024 | Injectafer, Enhertu |
| Acist Medical Systems, INC. | $36.08 | 2024 | |
| Alnylam Pharmaceuticals INC. | $31.55 | 2022-2025 | Amvuttra |
| Regeneron Healthcare Solutions, INC. | $26.84 | 2025 | Evkeeza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $23.12 | 2025 | |
| Scpharmaceuticals INC. | $22.55 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $18.90 | 2023 | Inpefa |
| Genzyme Corporation | $18.41 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $17.81 | 2024 | Uptravi |
| Philips North America LLC | $16.55 | 2025 | Mcot |
| Bayer Healthcare Pharmaceuticals INC. | $16.07 | 2024 | |
| Kiniksa Pharmaceuticals, Ltd. | $15.52 | 2022 | |
| Altathera Pharmaceuticals LLC | $14.23 | 2024 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.